Zosano Pharma Corp (NASDAQ:ZSAN) is witnessing a double digit rally in the pre-market session after the news.
As of 8:15, ZSAN stock jumped $0.191 or 25.67% to $0.935 on a heavy volume of 2.57 million shares. The stock has lost almost 70% from its 52-week high of $3.06.
Zosano Pharma Issues New Clinical Data
Zosano Pharma Announces Publication of Clinical Data Regarding the Long-term use of Qtrypta™ for the Treatment of Acute Migraine in The Journal of Headache and Pain
- announced that an article titled, “Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine” was published in The Journal of Headache and Pain.
- This open-label, multicenter observational study was designed to evaluate the safety and efficacy of the repeated use of Qtrypta™ in adults with migraine who had historically experienced at least 2 migraine attacks per month. The tolerability and efficacy results in this long-term study were consistent with the results observed in the Phase 2/3 ZOTRIP study.
- A total of 335 participants treated at least one migraine attack, and in total 5,963 migraine attacks were treated over the course of the study.
- The primary outcome measure was the percentage of participants experiencing treatment emergent adverse events over 12 months. Secondary outcomes included the percentage of migraine attacks for which pain freedom and most bothersome symptom freedom were achieved at two hours post-dose, and the percentage for which pain relief was achieved at two hours post-dose.
“The data published provide safety and efficacy findings for Qtyrpta™ when given repeatedly over the course of a year for the acute treatment of migraine,” said Don Kellerman, PharmD, vice president of clinical development and medical affairs of Zosano.